Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30260491 | 0.82 | SIRT6 (0.57) | SIRT6NAPRTALDH1A1NFKB1TSHR | |
| SCHEMBL27940385 | 0.78 | GABRA5 (0.38) | NAPRTAKR1B1GABRA5GABRB2GABRA1 | |
| SCHEMBL30260433 | 0.77 | SIRT6 (0.43) | SIRT6NAPRTALDH1A1NFKB1JUN | |
| SCHEMBL27837903 | 0.77 | GABRA5 (0.37) | NAPRTAKR1B1GABRA5GABRB2GABRA1 | |
| SCHEMBL28845160 | 0.77 | SIRT6 (0.41) | SIRT6ALDH1A1 | |
| SCHEMBL28940883 | 0.77 | GABRA5 (0.37) | NAPRTAKR1B1GABRA5GABRB2GABRA1 | |
| SCHEMBL27940310 | 0.77 | AGBL2 (0.38) | NAPRTAKR1B1GABRA5GABRB2GABRA1 | |
| SCHEMBL2729582 | 0.75 | GABRA5 (0.53) | NAPRTGABRA5GABRB2GABRA1GABRA4 | |
| SCHEMBL29593515 | 0.75 | AGBL2 (0.41) | GABRA5GABRB2GABRA1GABRA4HSD17B10 | |
| SCHEMBL1363917 | 0.75 | AGBL2 (0.41) | GABRA5GABRB2GABRA1GABRA4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101445505-B | The heteroaryl benzamide derivatives of GLK activator is used as in treatment diabetes | ASTRAZENECA (SWEDEN) AB (SE) | 2016-04-20 | — | — | CN | disclosed |
| CN-103797010-B | As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives | INCYTE HOLDINGS CORP. (US) | 2016-02-24 | — | — | CN | disclosed |
| CN-105324385-A | Bace inhibitors | LILLY CO ELI | 2016-02-10 | — | — | CN | disclosed |
| CN-103502237-B | Faah inhibitor | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-20 | — | — | CN | disclosed |
| CN-103732583-B | TRPV4 antagonist | GLAXOSMITHKLINE LLC (GB) | 2015-12-23 | — | — | CN | disclosed |
| CN-105164121-A | Perfluorinated cyclopropyl-fused 1, 3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use thereof | AMGEN INC | 2015-12-16 | — | — | CN | disclosed |
| CN-105111154-A | Novel technology for synthesizing 5-aminopyrazine-2-methanoic acid | SHANGHAI RAINBOW CHEMISTRY CO LTD | 2015-12-02 | — | — | CN | disclosed |
| CN-103717599-B | Indazole | PFIZER LTD. (GB) | 2015-11-25 | — | — | CN | disclosed |
| CN-104936956-A | Amino-substituted isothiazoles | Bayer Pharma AG | 2015-09-23 | — | — | CN | disclosed |
| CN-104837830-A | Novel pyrazine derivatives as CB2 receptor agonists | HOFFMANN LA ROCHE | 2015-08-12 | — | — | CN | disclosed |
| CN-101386618-A | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| CN-101258150-A | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| CN-101228162-A | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators | ASTRAZENECA AB (SE) | 2008-07-23 | — | — | CN | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| CN-101163692-A | Heterocyclic substituted piperazines with cxcr3 antagonist activity | PHARMACOPEIA DRUG DISCOVERY (US) | 2008-04-16 | — | — | CN | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673355-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | SIRT6 3609/4885NAPRT 3811/4885AKR1B1 2796/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | SIRT6 3743/4885NAPRT 4334/4885AKR1B1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.